BOSTON SCIENTIFIC CORP (BSX) Stock Price, Quote, News and Overview
NYSE:BSX - New York Stock Exchange, Inc. - US1011371077 - Common Stock - Currency: USD
BSX Quote, Performance and Key Statistics
93.58
-1.54 (-1.62%)
The current stock price of BSX is 93.58 USD. In the past month the price decreased by -7.06%. In the past year, price increased by 27.89%.
BSX Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 27.17 | 225.27B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.89 | 167.79B | ||
| SYK | STRYKER CORP | 27.86 | 129.62B | ||
| MDT | MEDTRONIC PLC | 15.32 | 104.91B | ||
| BDX | BECTON DICKINSON AND CO | 14.13 | 56.45B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.41 | 40.68B | ||
| IDXX | IDEXX LABORATORIES INC | 36.15 | 32.95B | ||
| RMD | RESMED INC | 23.85 | 30.97B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.47 | 27.69B | ||
| DXCM | DEXCOM INC | 40.07 | 25.92B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 14.83 | 21.89B | ||
| STE | STERIS PLC | 23.83 | 21.50B |
Related stock screener links
About BSX
Company Profile
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. Its MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. Its Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions. The company also owns the transcarotid artery revascularization (TCAR) platform.
Company Info
BOSTON SCIENTIFIC CORP
300 Boston Scientific Way
Marlborough MASSACHUSETTS 01752 US
CEO: Michael F. Mahoney
Employees: 48000
Company Website: https://www.bostonscientific.com/en-US/Home.html
Investor Relations: https://investors.bostonscientific.com
Phone: 15086834000
BOSTON SCIENTIFIC CORP / BSX FAQ
What is the stock price of BOSTON SCIENTIFIC CORP today?
The current stock price of BSX is 93.58 USD. The price decreased by -1.62% in the last trading session.
What is the ticker symbol for BOSTON SCIENTIFIC CORP stock?
The exchange symbol of BOSTON SCIENTIFIC CORP is BSX and it is listed on the New York Stock Exchange, Inc. exchange.
On which exchange is BSX stock listed?
BSX stock is listed on the New York Stock Exchange, Inc. exchange.
What is the price forecast or stock price prediction for BOSTON SCIENTIFIC CORP stock?
37 analysts have analysed BSX and the average price target is 119.71 USD. This implies a price increase of 27.92% is expected in the next year compared to the current price of 93.58. Check the BOSTON SCIENTIFIC CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BOSTON SCIENTIFIC CORP worth?
BOSTON SCIENTIFIC CORP (BSX) has a market capitalization of 138.41B USD. This makes BSX a Large Cap stock.
How many employees does BOSTON SCIENTIFIC CORP have?
BOSTON SCIENTIFIC CORP (BSX) currently has 48000 employees.
What are the support and resistance levels for BOSTON SCIENTIFIC CORP (BSX) stock?
BOSTON SCIENTIFIC CORP (BSX) has a support level at 91.27 and a resistance level at 106.11. Check the full technical report for a detailed analysis of BSX support and resistance levels.
Is BOSTON SCIENTIFIC CORP (BSX) expected to grow?
The Revenue of BOSTON SCIENTIFIC CORP (BSX) is expected to grow by 15.46% in the next year. Check the estimates tab for more information on the BSX EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BOSTON SCIENTIFIC CORP (BSX) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of BSX, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of BSX, evaluating the profitability, health, valuation and growth aspects
- BOSTON SCIENTIFIC CORP (BSX) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BOSTON SCIENTIFIC CORP (BSX) Sales and EPS estimates to see what analysts future expectations are.
- BOSTON SCIENTIFIC CORP (BSX) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BOSTON SCIENTIFIC CORP (BSX) Insider and Institutional Ownership to learn about the owners and their transactions.
- BOSTON SCIENTIFIC CORP (BSX) Stock Chart to make your own analysis
- BOSTON SCIENTIFIC CORP (BSX) Latest news and press-releases to stay up to date.
Does BOSTON SCIENTIFIC CORP (BSX) stock pay dividends?
BSX does not pay a dividend.
When does BOSTON SCIENTIFIC CORP (BSX) report earnings?
BOSTON SCIENTIFIC CORP (BSX) will report earnings on 2025-04-23, before the market open.
What is the Price/Earnings (PE) ratio of BOSTON SCIENTIFIC CORP (BSX)?
The PE ratio for BOSTON SCIENTIFIC CORP (BSX) is 37.28. This is based on the reported non-GAAP earnings per share of 2.51 and the current share price of 93.58 USD. Check the full fundamental report for a full analysis of the valuation metrics for BSX.
What is the Short Interest ratio of BOSTON SCIENTIFIC CORP (BSX) stock?
The outstanding short interest for BOSTON SCIENTIFIC CORP (BSX) is 0.88% of its float. Check the ownership tab for more information on the BSX short interest.
BSX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BSX. When comparing the yearly performance of all stocks, BSX is one of the better performing stocks in the market, outperforming 88.45% of all stocks.
BSX Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to BSX. While BSX belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
BSX Financial Highlights
Over the last trailing twelve months BSX reported a non-GAAP Earnings per Share(EPS) of 2.51. The EPS increased by 22.44% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 11.07% | ||
| ROA | 4.71% | ||
| ROE | 8.52% | ||
| Debt/Equity | 0.41 |
BSX Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 84% to BSX. The Buy consensus is the average rating of analysts ratings from 37 analysts.
For the next year, analysts expect an EPS growth of 15.1% and a revenue growth 15.46% for BSX